Arvidsson Per I, Sandberg Kristian, Sakariassen Kjell S
Science for Life Laboratory, Drug Discovery & Development Platform & Division of Translational Medicine & Chemical Biology, Department of Medical Biochemistry & Biophysics, Karolinska Institutet, Stockholm, Sweden.
Catalysis & Peptide Research Unit, University of KwaZulu-Natal, Durban, South Africa.
Future Sci OA. 2017 Apr 7;3(2):FSO176. doi: 10.4155/fsoa-2017-0013. eCollection 2017 Jun.
The Science for Life Laboratory Drug Discovery and Development Platform (SciLifeLab DDD) was established in Stockholm and Uppsala, Sweden, in 2014. It is one of ten platforms of the Swedish national SciLifeLab which support projects run by Swedish academic researchers with large-scale technologies for molecular biosciences with a focus on health and environment. SciLifeLab was created by the coordinated effort of four universities in Stockholm and Uppsala: Stockholm University, Karolinska Institutet, KTH Royal Institute of Technology and Uppsala University, and has recently expanded to other Swedish university locations. The primary goal of the SciLifeLab DDD is to support selected academic discovery and development research projects with tools and resources to discover novel lead therapeutics, either molecules or human antibodies. Intellectual property developed with the help of SciLifeLab DDD is wholly owned by the academic research group. The bulk of SciLifeLab DDD's research and service activities are funded from the Swedish state, with only consumables paid by the academic research group through individual grants.
瑞典生命科学实验室药物发现与开发平台(SciLifeLab DDD)于2014年在瑞典斯德哥尔摩和乌普萨拉成立。它是瑞典国家生命科学实验室的十个平台之一,该实验室利用分子生物科学的大规模技术支持瑞典学术研究人员开展的项目,重点关注健康与环境。生命科学实验室是由斯德哥尔摩和乌普萨拉的四所大学共同努力创建的:斯德哥尔摩大学、卡罗琳斯卡学院、皇家理工学院(KTH)和乌普萨拉大学,最近已扩展到瑞典其他大学所在地。SciLifeLab DDD的主要目标是通过工具和资源支持选定的学术发现与开发研究项目,以发现新型先导疗法,包括分子或人类抗体。在SciLifeLab DDD帮助下开发的知识产权归学术研究团队所有。SciLifeLab DDD的大部分研究和服务活动由瑞典国家资助,只有消耗品由学术研究团队通过个人资助支付。